Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Sep 25, 2015

Vela Diagnostics Sentosa SQ Thyroid Cancer Panel

Vela Diagnostics has launched the CE marked Sentosa SQ Thyroid Cancer Panel for next-generation sequencing-based variant detection and identification. The new panel is designed to simultaneously detect 105 hot spots in 10 genes associated with thyroid cancer. It exhibits a limit of detection of 5 percent variant frequency with a DNA requirement of 5 nanograms per library, and has a clinical sensitivity of 100 percent, the company said. The panel has been validated on the Sentosa NGS system, which automates sample extraction, library construction, template preparation, sequencing, analysis, and reporting.

AutoGen FlexStar+ DNA Extraction

AutoGen has launched the FlexStar+ automated DNA extraction platform. The new platform completely automates the DNA extraction process from primary tube sampling to final DNA elution into storage tubes. The system features protocols for 1-2 ml, 3-5 ml, and 6-10 ml of fresh or frozen whole blood and can draw samples from a variety of primary tube sizes, running up to 30 samples in a batch. It also features sample tracking and reporting software. AutoGen noted that unlike many other DNA extraction platforms that use magnetic bead technology, FlexStar+ uses Qiagen's FlexiGene chemistry.

Roche NimbleGen SeqCap EZ MedExome Target Enrichment Kit

Roche NimbleGen has globally launched the SeqCap EZ MedExome target enrichment kit, a comprehensive whole-exome sequencing solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs. The design targets the genome assembly GRCh38/hg38 (coordinates for hg19 annotation are also available) with comprehensive sequencing coverage of medically relevant and protein-coding regions. The product has been extensively optimized in design, empirical rebalancing, and manufacturing to increase coverage in hard-to-sequence regions for a more uniform and complete exome, Roche NimbleGen noted. SeqCap EZ MedExome produces greater than 85 percent on-target rate, and demonstrates high uniformity across the targeted region with about 98 percent sensitivity for SNP detection and greater than 99 percent specificity for SNP allele classification, according to Roche.

For more recent product launches please visit the New Products page on our website.